Invoke Bio develops personalized cancer immunotherapies using proprietary AI technology that models tumor-immune interactions with high accuracy. The company's ML engine integrates multifaceted biomolecular signals to predict immunogenic targets, achieving 89% accuracy compared to the 10-30% industry standard. Invoke Bio offers investigational neoantigen vaccines through the FDA's Expanded Access program for eligible patients.
Funding
Funding not disclosed
Founders
Product
Problem
Standard cancer immunotherapies are designed for broad patient populations rather than individual tumors, limiting their effectiveness. Each tumor has a unique molecular profile, and conventional approaches fail to account for this heterogeneity, resulting in suboptimal immune responses and reduced treatment efficacy.
Solution
Invoke Bio uses proprietary AI technology to develop 100% custom-tailored immunotherapies for people living with cancer. The company's machine learning engine integrates multifaceted biomolecular signals to model tumor-immune interaction over time, achieving 89% accuracy in immunogenic target prediction—three times more accurate than industry and academic benchmarks. This greater target prediction accuracy translates into a stronger, more targeted immune response capable of recognizing and fighting an individual's unique cancer. Invoke Bio develops investigational personalized cancer vaccines and works with physicians and the FDA's Expanded Access pathway to support patient access to its neoantigen vaccine program.
Target Audience
Primary customers are cancer patients seeking access to investigational personalized immunotherapies through the FDA's Expanded Access program, as well as biopharma companies, diagnostics firms, and research institutions looking to collaborate on personalized cancer treatment development.
Features
- Proprietary ML engine that integrates multifaceted biomolecular signals to model tumor-immune interaction over time
- Immunogenic target prediction accuracy of 89%, compared to the 10-30% industry standard
- 100% custom-tailored neoantigen vaccine development for each individual patient's tumor profile
- FDA Expanded Access (Compassionate Use) pathway support for eligible patients
- Direct collaboration with physicians and care teams for patient access
- Partnership opportunities for biopharma companies, diagnostics firms, and research institutions